Radioligand therapy extends progression-free survival with manageable safety profile in advanced prostate cancer

New data on prolonged prostate-specific antigen (PSA) progression and adverse events grouped by safety topic of interest from the PSMAfore study underscore the statistically significant and clinically meaningful radiographic progression-free survival (rPFS) benefit of [177Lu]Lu-PSMA-617 radioligand therapy for patients with taxane-naive metastatic castration-resistant prostate cancer (mCRPC).

This article was originally published on

You may also be interested in:

Read More:

Lawyers Lookup